Baricitinib as monotherapy for treatment of rheumatoid arthritis: analysis of real-world data
Current Medical Research and Opinion 2024;40:1993–2002 doi: 10.1080/03007995.2024.2416979.
Edwards et al. report on real-world data for baricitinib monotherapy in rheumatoid arthritis, showing significant disease activity reduction across multiple registries and observational studies. These findings reinforce the viability of baricitinib monotherapy in clinical practice for RA patients, complementing existing guidelines.
A total of 932 RA patients treated with baricitinib monotherapy were assessed across several registries, with 40.7%–93.8% achieving remission or low disease activity within 6–12 months. These results were benchmarked against combination therapy outcomes.
Keywords:
